Similar Search Results

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25

Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …

Persistent link: https://www.econbiz.de/10012291135

Arzneimittel in der Dritten Welt : die Rolle der deutschen Pharmaindustrie

Hartog, Robert; Schulte-Sasse, Hermann - 1993

Persistent link: https://www.econbiz.de/10000866882

Mensch und Medikament : die Pharmaindustrie im Spannungsfeld der Gesellschaft

Ortwein, Ingeborg (contributor); … - 1993 - Orig.-Ausg

Persistent link: https://www.econbiz.de/10000868828

Pharma-Daten

Berlin : BPI; anfangs: Frankfurt, M. : BPI - Nachgewiesen 1972 - 1974; 5.1975 -

Persistent link: https://www.econbiz.de/10000363330

Integrierte Versorgung und die Rolle der Pharmaindustrie

Koch, Kristian - 2009

Persistent link: https://www.econbiz.de/10003862841

Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany

Herr, Annika; Suppliet, Moritz - 2012

Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …